Exploring the MIR143-UPAR Axis for the Inhibition of Human Prostate Cancer Cells In Vitro and In Vivo
Module III – CAS in Radiopharmaceutical Chemistry/Radiopharmacy | ETH Zurich
Analysis of cellular and molecular antitumor effects upon inhibition of SATB1 in glioblastoma cells
Mitarbeiter des Rudolf-Boehm-Institutes
Leipziger Pharmakologen forschen an Molekülen gegen Prostatakrebs
Achim AIGNER | University of Leipzig, Leipzig | Institute of Pharmacology, Pharmacy and Toxicology
Mitarbeiter des Rudolf-Boehm-Institutes
Achim AIGNER | University of Leipzig, Leipzig | Institute of Pharmacology, Pharmacy and Toxicology
Foresee Edebi sanatlar yelken achim aigner leipzig university germany Tren istasyonu ilgisiz yerine getirmek
Mitarbeiter des Rudolf-Boehm-Institutes
SiRNA-transfection of SKOV-3-Luc cells with the Biontex K2® Transfection System Dipl.-Chem. Alexander Ewe, Prof. Achim Aigner U
European Technology Platform on Nanomedicine
Untersuchung der biologischen Aktivität von Nanopartikeln in Tumor- schnittkulturen
Achim AIGNER | University of Leipzig, Leipzig | Institute of Pharmacology, Pharmacy and Toxicology
Achim Aigner | Leipzig University, Germany | Pharmaceutica 2017 | Conferenceseries
Let Life Sciences meet you Let Life Sciences meet you
Nanoparticle-mediated delivery of small RNA molecules in tumor therapy
MedTech-2022 Conferences | MedTech -2022 | MedTech 2022 Events | Pharma Industry and MedTech | MedTech Conferences | MedTech Meetings | Pharma Industry and MedTech | | Pharma Industry and MedTech Congress
C:/Users/julia/biotechnologische Studenteninitiative (btS) e.V/Leipzig - ScieGuide 2019/ScieGuide final 08.08/ScieGuide070819.sl
Achim AIGNER | University of Leipzig, Leipzig | Institute of Pharmacology, Pharmacy and Toxicology
Biocompatibility and Efficacy of Oligomaltose-Grafted Poly(ethylene imine)s (OM-PEIs) for in Vivo Gene Delivery
Multiple effects of the special ATâ•'rich binding protein 1 (SATB1) in colon carcinoma
Analysis of SATB1 in Head and Neck Squamous Cell Carcinoma
Perspectives, issues and solutions in RNAi therapy: the expected and the less expected
